Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 235

1.

[Review of the novelties from the 2017 ECTRIMS Congress, presented at the 10th Post-ECTRIMS Meeting (II)].

Fernandez O, Tintore M, Saiz A, Calles-Hernandez MC, Comabella M, Ramio-Torrenta L, Oterino A, Izquierdo G, Tellez N, Garcia-Merino JA, Brieva L, Arnal-Garcia C, Aladro Y, Mendibe-Bilbao MM, Meca-Lallana JE, Romero-Pinel L, Ginestal R, Martinez-Gines ML, Arroyo R, Rodriguez-Antiguedad A.

Rev Neurol. 2018 Jul 15;67(2):50-62. Review. Spanish.

2.

[Review of the novelties from the 2017 ECTRIMS Congress, presented at the 10th Post-ECTRIMS Meeting (I)].

Fernandez O, Tintore M, Saiz A, Calles-Hernandez MC, Comabella M, Ramio-Torrenta L, Oterino A, Izquierdo G, Tellez N, Garcia-Merino JA, Brieva L, Arnal-Garcia C, Aladro Y, Mendibe-Bilbao MM, Meca-Lallana JE, Romero-Pinel L, Ginestal R, Martinez-Gines ML, Arroyo R, Rodriguez-Antiguedad A.

Rev Neurol. 2018 Jul 1;67(1):15-27. Review. Spanish.

3.

The role of the cerebellum in multiple sclerosis-150 years after Charcot.

Parmar K, Stadelmann C, Rocca MA, Langdon D, D'Angelo E, D'Souza M, Burggraaff J, Wegner C, Sastre-Garriga J, Barrantes-Freer A, Dorn J, Uitdehaag BMJ, Montalban X, Wuerfel J, Enzinger C, Rovira A, Tintore M, Filippi M, Kappos L, Sprenger T; MAGNIMS study group.

Neurosci Biobehav Rev. 2018 Jun;89:85-98. doi: 10.1016/j.neubiorev.2018.02.012. Epub 2018 Feb 23. Review.

PMID:
29477616
4.

Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report.

Camara-Lemarroy CR, Castilló J, Sastre-Garriga J, Tintore M, Montalban X.

Mult Scler. 2018 Feb 1:1352458518761185. doi: 10.1177/1352458518761185. [Epub ahead of print]

PMID:
29473796
5.

The value of oligoclonal bands in the multiple sclerosis diagnostic criteria.

Arrambide G, Tintore M, Espejo C, Auger C, Castillo M, Río J, Castilló J, Vidal-Jordana A, Galán I, Nos C, Mitjana R, Mulero P, de Barros A, Rodríguez-Acevedo B, Midaglia L, Sastre-Garriga J, Rovira A, Comabella M, Montalban X.

Brain. 2018 Apr 1;141(4):1075-1084. doi: 10.1093/brain/awy006.

PMID:
29462277
6.

Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome.

Matute-Blanch C, Villar LM, Álvarez-Cermeño JC, Rejdak K, Evdoshenko E, Makshakov G, Nazarov V, Lapin S, Midaglia L, Vidal-Jordana A, Drulovic J, García-Merino A, Sánchez-López AJ, Havrdova E, Saiz A, Llufriu S, Alvarez-Lafuente R, Schroeder I, Zettl UK, Galimberti D, Ramió-Torrentà L, Robles R, Quintana E, Hegen H, Deisenhammer F, Río J, Tintoré M, Sánchez A, Montalban X, Comabella M.

Brain. 2018 Apr 1;141(4):1085-1093. doi: 10.1093/brain/awy021.

PMID:
29452342
7.

Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations.

De Stefano N, Giorgio A, Tintoré M, Pia Amato M, Kappos L, Palace J, Yousry T, Rocca MA, Ciccarelli O, Enzinger C, Frederiksen J, Filippi M, Vrenken H, Rovira À; MAGNIMS study group.

Mult Scler. 2018 Feb;24(2):214-221. doi: 10.1177/1352458517717808. No abstract available.

PMID:
29451440
8.

Multiple sclerosis risk perception and acceptance for Brazilian patients.

Bichuetti DB, Franco CA, Elias I, Mendonça ACR, Carvalho LFD, Diniz DS, Tur C, Tintoré M, Oliveira EML.

Arq Neuropsiquiatr. 2018 Jan;76(1):6-12. doi: 10.1590/0004-282X20170167.

9.

Cervical Cord Atrophy and Long-Term Disease Progression in Patients with Primary-Progressive Multiple Sclerosis.

Aymerich FX, Auger C, Alonso J, Alberich M, Sastre-Garriga J, Tintoré M, Montalban X, Rovira A.

AJNR Am J Neuroradiol. 2018 Feb;39(2):399-404. doi: 10.3174/ajnr.A5495. Epub 2017 Dec 28.

PMID:
29284602
10.

Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study.

Filippi M, Preziosa P, Meani A, Ciccarelli O, Mesaros S, Rovira A, Frederiksen J, Enzinger C, Barkhof F, Gasperini C, Brownlee W, Drulovic J, Montalban X, Cramer SP, Pichler A, Hagens M, Ruggieri S, Martinelli V, Miszkiel K, Tintorè M, Comi G, Dekker I, Uitdehaag B, Dujmovic-Basuroski I, Rocca MA.

Lancet Neurol. 2018 Feb;17(2):133-142. doi: 10.1016/S1474-4422(17)30469-6. Epub 2017 Dec 21.

PMID:
29275979
11.

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.

Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Review.

PMID:
29275977
12.

Lesion topographies in multiple sclerosis diagnosis: A reappraisal.

Arrambide G, Tintore M, Auger C, Río J, Castilló J, Vidal-Jordana A, Galán I, Nos C, Comabella M, Mitjana R, Mulero P, de Barros A, Rodríguez-Acevedo B, Midaglia L, Sastre-Garriga J, Rovira A, Montalban X.

Neurology. 2017 Dec 5;89(23):2351-2356. doi: 10.1212/WNL.0000000000004715. Epub 2017 Nov 3.

13.

The optic nerve should be included as one of the typical CNS regions for establishing dissemination in space when diagnosing MS - No.

Tintoré M, Montalban X.

Mult Scler. 2018 Feb;24(2):123-125. doi: 10.1177/1352458517729451. Epub 2017 Oct 23. No abstract available.

PMID:
29059000
14.

Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates.

Sepúlveda M, Aldea M, Escudero D, Llufriu S, Arrambide G, Otero-Romero S, Sastre-Garriga J, Romero-Pinel L, Martínez-Yélamos S, Sola-Valls N, Armangué T, Sotoca J, Escartín A, Robles-Cedeño R, Ramió-Torrentà L, Presas-Rodríguez S, Ramo-Tello C, Munteis E, Pelayo R, Gubieras L, Brieva L, Ortiz N, Hervás M, Mañé-Martínez MA, Cano A, Vela E, Tintoré M, Blanco Y, Montalban X, Graus F, Saiz A.

Mult Scler. 2017 Oct 1:1352458517735191. doi: 10.1177/1352458517735191. [Epub ahead of print]

PMID:
28984163
15.

Radiologically isolated syndrome in children: Clinical and radiologic outcomes.

Makhani N, Lebrun C, Siva A, Brassat D, Carra Dallière C, de Seze J, Du W, Durand Dubief F, Kantarci O, Langille M, Narula S, Pelletier J, Rojas JI, Shapiro ED, Stone RT, Tintoré M, Uygunoglu U, Vermersch P, Wassmer E, Okuda DT, Pelletier D.

Neurol Neuroimmunol Neuroinflamm. 2017 Sep 25;4(6):e395. doi: 10.1212/NXI.0000000000000395. eCollection 2017 Nov.

16.

SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.

Bove R, Chitnis T, Cree BA, Tintoré M, Naegelin Y, Uitdehaag BM, Kappos L, Khoury SJ, Montalban X, Hauser SL, Weiner HL; SUMMIT Consortium.

Mult Scler. 2017 Aug 1:1352458517726657. doi: 10.1177/1352458517726657. [Epub ahead of print]

PMID:
28847219
17.

Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab.

Mulero P, Auger C, Parolin L, Fonseca E, Requena M, Rio J, Tintoré M, Rovira A, Montalban X.

Mult Scler. 2018 Mar;24(3):358-360. doi: 10.1177/1352458517711569. Epub 2017 Jun 23.

PMID:
28643544
18.

Cumulative Dose of Macrocyclic Gadolinium-Based Contrast Agent Improves Detection of Enhancing Lesions in Patients with Multiple Sclerosis.

Rovira A, Auger C, Huerga E, Corral JF, Mitjana R, Sastre-Garriga J, Tintoré M, Montalban X.

AJNR Am J Neuroradiol. 2017 Aug;38(8):1486-1493. doi: 10.3174/ajnr.A5253. Epub 2017 Jun 15.

PMID:
28619842
19.

Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations.

Vidal-Jordana A, Sastre-Garriga J, Pareto D, Tur C, Arrambide G, Otero-Romero S, Huerga E, Mitjana R, Auger C, Tintoré M, Rovira A, Montalban X.

Mult Scler. 2018 May;24(6):721-727. doi: 10.1177/1352458517707070. Epub 2017 Apr 26.

PMID:
28445084
20.

Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor.

Arrambide G, Rovira A, Sastre-Garriga J, Tur C, Castilló J, Río J, Vidal-Jordana A, Galán I, Rodríguez-Acevedo B, Midaglia L, Nos C, Mulero P, Arévalo MJ, Comabella M, Huerga E, Auger C, Montalban X, Tintore M.

Mult Scler. 2018 Mar;24(3):301-312. doi: 10.1177/1352458517697830. Epub 2017 Mar 16.

PMID:
28301287
21.

Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients.

Río J, Rovira À, Tintoré M, Otero-Romero S, Comabella M, Vidal-Jordana Á, Galán I, Castilló J, Arrambide G, Nos C, Tur C, Pujal B, Auger C, Sastre-Garriga J, Montalban X.

Mult Scler. 2018 Mar;24(3):322-330. doi: 10.1177/1352458517698052. Epub 2017 Mar 13.

PMID:
28287331
22.

Treatment decisions in multiple sclerosis - insights from real-world observational studies.

Trojano M, Tintore M, Montalban X, Hillert J, Kalincik T, Iaffaldano P, Spelman T, Sormani MP, Butzkueven H.

Nat Rev Neurol. 2017 Feb;13(2):105-118. doi: 10.1038/nrneurol.2016.188. Epub 2017 Jan 13. Review.

PMID:
28084327
23.

The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction.

Tintoré M, Alexander M, Costello K, Duddy M, Jones DE, Law N, O'Neill G, Uccelli A, Weissert R, Wray S.

Patient Prefer Adherence. 2016 Dec 22;11:33-45. doi: 10.2147/PPA.S115090. eCollection 2017.

24.

Symptom tracking: from clinically isolated syndrome to advanced multiple sclerosis.

Tintoré M.

Neurodegener Dis Manag. 2016 Dec;6(6s):27-29. No abstract available.

PMID:
27874490
25.

Sustained reduction of MS disability: New player in comparing disease-modifying treatments.

Bielekova B, Tintore M.

Neurology. 2016 Nov 8;87(19):1966-1967. Epub 2016 Oct 12. No abstract available.

PMID:
27733564
26.

Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis.

Tintore M, Otero-Romero S, Río J, Arrambide G, Pujal B, Tur C, Galán I, Comabella M, Nos C, Arévalo MJ, Vidal-Jordana A, Castilló J, Rodríguez-Acevedo B, Midaglia L, Mitjana R, Auger C, Sastre-Garriga J, Rovira À, Montalban X.

Neurology. 2016 Sep 27;87(13):1368-74. doi: 10.1212/WNL.0000000000003144. Epub 2016 Aug 26.

PMID:
27566747
27.

Neurofilament light chain level is a weak risk factor for the development of MS.

Arrambide G, Espejo C, Eixarch H, Villar LM, Alvarez-Cermeño JC, Picón C, Kuhle J, Disanto G, Kappos L, Sastre-Garriga J, Pareto D, Simon E, Comabella M, Río J, Nos C, Tur C, Castilló J, Vidal-Jordana A, Galán I, Arévalo MJ, Auger C, Rovira A, Montalban X, Tintore M.

Neurology. 2016 Sep 13;87(11):1076-84. doi: 10.1212/WNL.0000000000003085. Epub 2016 Aug 12. Erratum in: Neurology. 2016 Nov 8;87(19):2068.

28.

Multiple sclerosis: Dimethyl fumarate is coming of age.

Tintoré M, Sastre-Garriga J.

Nat Rev Neurol. 2016 Aug;12(8):436-7. doi: 10.1038/nrneurol.2016.106. Epub 2016 Jul 22. No abstract available.

PMID:
27448183
29.

Grey matter atrophy is associated with disability increase in natalizumab-treated patients.

Ciampi E, Pareto D, Sastre-Garriga J, Vidal-Jordana A, Tur C, Río J, Tintoré M, Auger C, Rovira A, Montalban X.

Mult Scler. 2017 Apr;23(4):556-566. doi: 10.1177/1352458516656808. Epub 2016 Jul 11.

PMID:
27354019
30.

Assessing response to interferon-β in a multicenter dataset of patients with MS.

Sormani MP, Gasperini C, Romeo M, Rio J, Calabrese M, Cocco E, Enzingher C, Fazekas F, Filippi M, Gallo A, Kappos L, Marrosu MG, Martinelli V, Prosperini L, Rocca MA, Rovira A, Sprenger T, Stromillo ML, Tedeschi G, Tintorè M, Tortorella C, Trojano M, Montalban X, Pozzilli C, Comi G, De Stefano N; MAGNIMS study group.

Neurology. 2016 Jul 12;87(2):134-40. doi: 10.1212/WNL.0000000000002830. Epub 2016 Jun 15.

PMID:
27306626
31.

Improved Automatic Detection of New T2 Lesions in Multiple Sclerosis Using Deformation Fields.

Cabezas M, Corral JF, Oliver A, Díez Y, Tintoré M, Auger C, Montalban X, Lladó M, Pareto D, Rovira À.

AJNR Am J Neuroradiol. 2016 Jun 9. [Epub ahead of print]

PMID:
27282863
32.

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica.

Waters P, Reindl M, Saiz A, Schanda K, Tuller F, Kral V, Nytrova P, Sobek O, Nielsen HH, Barington T, Lillevang ST, Illes Z, Rentzsch K, Berthele A, Berki T, Granieri L, Bertolotto A, Giometto B, Zuliani L, Hamann D, van Pelt ED, Hintzen R, Höftberger R, Costa C, Comabella M, Montalban X, Tintoré M, Siva A, Altintas A, Deniz G, Woodhall M, Palace J, Paul F, Hartung HP, Aktas O, Jarius S, Wildemann B, Vedeler C, Ruiz A, Leite MI, Trillenberg P, Probst M, Saschenbrecker S, Vincent A, Marignier R.

J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):1005-15. doi: 10.1136/jnnp-2015-312601. Epub 2016 Apr 25.

33.

CSF examination still has value in the diagnosis of MS - Commentary.

Arrambide G, Tintore M.

Mult Scler. 2016 Jul;22(8):997-8. doi: 10.1177/1352458516642033. Epub 2016 Apr 8. No abstract available.

PMID:
27059063
34.

Brain Volume Loss During the First Year of Interferon-Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics.

Vidal-Jordana A, Sastre-Garriga J, Pérez-Miralles F, Pareto D, Rio J, Auger C, Tintoré M, Rovira A, Montalban X.

J Neuroimaging. 2016 Sep;26(5):532-8. doi: 10.1111/jon.12337. Epub 2016 Mar 2.

PMID:
26935253
35.

Lesion filling effect in regional brain volume estimations: a study in multiple sclerosis patients with low lesion load.

Pareto D, Sastre-Garriga J, Aymerich FX, Auger C, Tintoré M, Montalban X, Rovira A.

Neuroradiology. 2016 May;58(5):467-74. doi: 10.1007/s00234-016-1654-5. Epub 2016 Feb 4.

PMID:
26847633
36.

MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.

Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, Rovira A, Sastre-Garriga J, Tintorè M, Frederiksen JL, Gasperini C, Palace J, Reich DS, Banwell B, Montalban X, Barkhof F; MAGNIMS Study Group.

Lancet Neurol. 2016 Mar;15(3):292-303. doi: 10.1016/S1474-4422(15)00393-2. Epub 2016 Jan 26. Review.

37.

The first volume of MSJ-ETC.

Cohen JA, Kim HJ, Tintore M.

Mult Scler J Exp Transl Clin. 2016 Jan 22;2:2055217315626042. doi: 10.1177/2055217315626042. eCollection 2016 Jan-Dec. No abstract available.

38.

Advances in the management of multiple sclerosis symptoms: pathophysiology and assessment of spasticity in multiple sclerosis.

Tintoré M.

Neurodegener Dis Manag. 2015;5(6 Suppl):15-7. doi: 10.2217/nmt.15.56.

PMID:
26611266
39.

Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome.

Kantarci OH, Lebrun C, Siva A, Keegan MB, Azevedo CJ, Inglese M, Tintoré M, Newton BD, Durand-Dubief F, Amato MP, De Stefano N, Sormani MP, Pelletier D, Okuda DT.

Ann Neurol. 2016 Feb;79(2):288-94. doi: 10.1002/ana.24564. Epub 2015 Dec 29.

PMID:
26599831
40.

Gold-Coated Superparamagnetic Nanoparticles for Single Methyl Discrimination in DNA Aptamers.

Tintoré M, Mazzini S, Polito L, Marelli M, Latorre A, Somoza Á, Aviñó A, Fàbrega C, Eritja R.

Int J Mol Sci. 2015 Nov 18;16(11):27625-39. doi: 10.3390/ijms161126046.

41.

Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses.

Ramo-Tello C, Tintoré M, Rovira A, Ramió-Torrenta L, Brieva L, Saiz A, Cano A, Carmona O, Hervás JV, Grau-López L.

Mult Scler. 2016 Jan;22(1):117-21. doi: 10.1177/1352458515590648. Epub 2015 Jun 25.

PMID:
26540732
42.

Peripheral blood non-MAIT CD8+CD161hi cells are decreased in relapsing-remitting multiple sclerosis patients treated with interferon beta.

Negrotto L, Cantó E, Río J, Tintoré M, Montalban X, Comabella M.

J Neuroimmunol. 2015 Nov 15;288:98-101. doi: 10.1016/j.jneuroim.2015.09.007. Epub 2015 Sep 25.

PMID:
26531701
43.

Synthesis of oligonucleotides carrying fluorescently labelled O(6)-alkylguanine for measuring hAGT activity.

Tintoré M, Grijalvo S, Eritja R, Fàbrega C.

Bioorg Med Chem Lett. 2015 Nov 15;25(22):5208-11. doi: 10.1016/j.bmcl.2015.09.065. Epub 2015 Sep 30.

PMID:
26459209
44.

Juxtacortical Lesions and Cortical Thinning in Multiple Sclerosis.

Pareto D, Sastre-Garriga J, Auger C, Vives-Gilabert Y, Delgado J, Tintoré M, Montalban X, Rovira A.

AJNR Am J Neuroradiol. 2015 Dec;36(12):2270-6. doi: 10.3174/ajnr.A4485. Epub 2015 Oct 8.

45.

Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Wattjes MP, Rovira À, Miller D, Yousry TA, Sormani MP, de Stefano MP, Tintoré M, Auger C, Tur C, Filippi M, Rocca MA, Fazekas F, Kappos L, Polman C, Frederik Barkhof, Xavier Montalban; MAGNIMS study group.

Nat Rev Neurol. 2015 Oct;11(10):597-606. doi: 10.1038/nrneurol.2015.157. Epub 2015 Sep 15. Review.

PMID:
26369511
46.

GABAergic Pharmacotherapy in the Treatment of Motor Disorders of the Central Nervous System.

Gazulla J, Ruiz-Gazulla C, Tintore M.

Curr Pharm Des. 2015;21(34):4989-95. Review.

PMID:
26365142
47.

Review of the novelties from the 2014 ECTRIMS-ACTRIMS Joint Congress, presented at the 7th Post-ECTRIMS Meeting (II).

Fernandez O, Alvarez-Cermeno JC, Arroyo R, Brieva L, Calles-Hernandez MC, Casanova-Estruch B, Comabella M, Garcia-Merino JA, Ginestal R, Izquierdo G, Meca-Lallana JE, Mendibe-Bilbao MM, Montalban X, Munoz-Garcia D, Olascoaga J, Oliva-Nacarino P, Oreja-Guevara C, Ramio-Torrenta L, Romero-Pinel L, Rodriguez-Antiguedad A, Saiz A, Tintore M, Grupo Post-Ectrims GP.

Rev Neurol. 2015 Sep 16;61(6):271-83. English, Spanish.

48.

[Review of the novelties from the 2014 ECTRIMS-ACTRIMS Joint Congress, presented at the 7th Post-ECTRIMS meeting (I)].

Fernandez O, Alvarez-Cermeno JC, Arroyo R, Brieva L, Calles-Hernandez MC, Casanova-Estruch B, Comabella M, Garcia-Merino JA, Ginestal R, Izquierdo G, Meca-Lallana JE, Mendibe-Bilbao MM, Montalban X, Munoz-Garcia D, Olascoaga J, Oliva-Nacarino P, Oreja-Guevara C, Ramio-Torrenta L, Romero-Pinel L, Rodriguez-Antiguedad A, Saiz A, Tintore M, Grupo Post-Ectrims GP.

Rev Neurol. 2015 Sep 1;61(5):215-24. Spanish.

49.

The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level-NO.

Arrambide G, Espejo C, Tintore M.

Mult Scler. 2015 Sep;21(10):1240-2. doi: 10.1177/1352458515589774. Epub 2015 Aug 4. No abstract available.

PMID:
26242692
50.

Predictive value of early brain atrophy on response in patients treated with interferon β.

Pérez-Miralles FC, Sastre-Garriga J, Vidal-Jordana A, Río J, Auger C, Pareto D, Tintoré M, Rovira A, Montalban X.

Neurol Neuroimmunol Neuroinflamm. 2015 Jul 2;2(4):e132. doi: 10.1212/NXI.0000000000000132. eCollection 2015 Aug.

Supplemental Content

Loading ...
Support Center